Today "a milestone in the evolution of personalized therapies for rare & ultra-rare inborn errors of metabolism" —the 1st human to undergo custom genome editing —outgrowth of decades of NIH funded research nejm.org/doi/full/10.10… nejm.org/doi/full/10.10… NEJM

Here are my top 10 for gynecologic cancers at #ASCO25 Can't wait to see you all there! Debra Richardson, M.D. Shannon Westin, MD, MPH, FASCO BJ Rimel Robert Wenham what are you excited to see?

An exceptional new NEJM review on cancer of unknown origin nejm.org/doi/full/10.10…

At #ASCO25, MD Anderson is presenting more than 120 studies, including five emerging therapies that could reshape cancer care. These include treatments for thyroid and colorectal cancers and a rare leukemia. Read more: spr.ly/6016N2lAK #EndCancer

Cancer of unknown primary site encompasses a heterogeneous group of metastatic cancers with an unidentified primary site of origin. Putative site-specific therapy and empirical chemotherapy are acceptable treatment options. Read the Clinical Practice article “Cancer of Unknown

First Phase 2 randomized trial of engineered T cells for a solid tumor—GI cancer— with some encouraging results The Lancet #ASCO25 thelancet.com/journals/lance…

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

The remarkable benefit of exercise was just extended to improved survival after cancer in a randomized trial NEJM #ASCO25 nejm.org/doi/full/10.10…

The most practice changing trial from #ASCO25 is now live on NEJM .If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival. Perfect case example of a #cancergroundshot trial.

"Overall survival & quality of life superiority in modern phase Ill oncology trials." Phase Ill onc RCTs are commonly called "positive." But this is usually based on alternative endpoint improvement. Gains in either OS or QOL are uncommon, & exceedingly rare in combo. #ASCO25

Phase 3 oncology RCTs often report positive results based on alternative end points, but actual improvements in overall survival or quality of life are rare, highlighting need to prioritize these outcomes in future research & regulatory processes. #ASCO25 ja.ma/3FCoVHI

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

A blood-based test demonstrated acceptable accuracy for colorectal cancer detection in an average-risk colorectal cancer screening population. #ASCO25 ja.ma/3HfAXHJ

Fertility preservation is a key concern for many women with cancer, yet it’s often overlooked. Dr. Terri Woodard highlights the need to address this early in treatment planning. Timely referral to a reproductive specialist can ease distress and expand options. #ASCO25 #EndCancer

Grateful to be attending my first ASCO as I near the end of my first year of fellowship. A special thank you to all the patients who participate in our trials, and to Drs. Shannon Westin, MD, MPH, FASCO and Anil Sood for the opportunity to work with them on this Phase I!

Nothing is possible without mentorship and sponsorship. Thank you Shannon Westin, MD, MPH, FASCO for believing in this budding clinical trialist and advocating for me (and so many other trainees) to be in the room where it happens! #ASCO25

“The addition of maintenance olaparib really shines in the DNA mismatch repair proficient population,” said our Dr. Shannon Westin, MD, MPH, FASCO of exploratory analyses of longitudinal ctDNA from the DUO-E trial at #ASCO25. ASCO #EndCancer

Remember: it’s only “practice-changing” if, through shared decision-making, our patients discern benefit and are willing to switch or add to their therapies post-#ASCO25 Thanks to ASCO for these useful after-conference resources 👇🏻

Excited to share my OB/GYN @ Stanford residency research project in EJGO: When performed by a skilled surgeon, SSH may be something to consider for the right patient! Thanks to Drs. Karam, @s_somasegar, and Moon for the mentorship, and Jiaqi for help with propensity-matching.

We overestimate willpower. We underestimate context. Situation modification is the simple, science-backed idea that you can change your behavior by changing your surroundings. Put your phone in another room. Sit next to what you want to focus on. Create friction for